Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma

被引：11

作者：

Nagai, Takashi ^{[1
]}

Naiki, Taku ^{[1
]}

Isobe, Teruki ^{[1
]}

Sugiyama, Yosuke ^{[2
]}

Etani, Toshiki ^{[1
]}

Iida, Keitaro ^{[1
]}

Nozaki, Satoshi ^{[1
]}

Noda, Yusuke ^{[1
,3
]}

Shimizu, Nobuhiko ^{[1
]}

Tasaki, Yoshihiko ^{[2
]}

Mimura, Yoshihisa ^{[2
]}

Banno, Rika ^{[4
]}

Kubota, Hiroki ^{[5
]}

Hamamoto, Shuzo ^{[1
]}

Kawai, Noriyasu ^{[1
]}

Yasui, Takahiro ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrourol, Nagoya, Aichi, Japan

[2] Nagoya City Univ Hosp, Dept Pharm, Nagoya, Aichi, Japan

[3] Toyota Kosei Hosp, Dept Urol, Toyota, Japan

[4] Konan Kosei Hosp, Dept Urol, Konan, Japan

[5] Kainan Hosp, Dept Urol, Yatomi, Japan

来源：

IN VIVO | 2021年 / 35卷 / 05期

关键词：

Metastatic urothelial carcinoma; modified Glasgow prognostic score; biomarker; prognosis; EARLY PALLIATIVE CARE; BLADDER-CANCER; CHEMOTHERAPY;

D O I：

10.21873/invivo.12565

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: Predicting the prognosis of metastatic urothelial carcinoma (mUC) patients is needed for clinical decisions. We examined the value of a modified Glasgow prognostic score (mGPS) as a predictive marker for mUC patients. Patients and Methods: In a multicenter study, 68 mUC patients received short hydration gemcitabine/ cisplatin (shGC) and 74 received pembrolizumab (PEM). Patients were allocated according to mGPS. Progression-free (PFS) and cancer-specific (CSS) survival were examined. Results: Higher mGPS reflected poorer PFS and CSS in shGC (p=0.03, p<0.0001, respectively) and PEM (p=0.02, p<0.001, respectively) patients. PFS for the high mGPS group was longer than that of the low mGPS group in the two cohorts (p <0.0001 for both), with similar CSS results (p<0.0001 and p<0.001, respectively). Multivariate analyses revealed high mGPS was a risk factor for poor CSS in both cohorts (HR=3.55, p<0.001, and HR=2.21, p<0.01, respectively). Conclusion: In the mUC patients receiving shGC or PEM, mGPS was a predictive prognostic marker.

引用

页码：2793 / 2800

页数：8

共 22 条

[1] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[2] Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Bellmunt, Joaquim
Choueiri, Toni K.
Fougeray, Ronan
Schutz, Fabio A. B.
Salhi, Yacine
Winquist, Eric
Culine, Stephane
von der Maase, Hans
Vaughn, David J.
Rosenberg, Jonathan E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1850 - 1855
[3] Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis
Etani, Toshiki
Naiki, Taku
Sugiyama, Yosuke
Nagai, Takashi
Iida, Keitaro
Noda, Yusuke
Shimizu, Nobuhiko
Tasaki, Yoshihiko
Mimura, Yoshihisa
Okada, Tomoki
Banno, Rika
Kubota, Hiroki
Hamamoto, Shuzo
Ando, Ryosuke
Kawai, Noriyasu
Yasui, Takahiro
[J]. ONCOLOGY, 2020, 98 (12) : 876 - 883
[4] Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy A Multicenter Experience
Ferro, Matteo
De Cobelli, Ottavio
Buonerba, Carlo
Di Lorenzo, Giuseppe
Capece, Marco
Bruzzese, Dario
Autorino, Riccardo
Bottero, Danilo
Cioffi, Antonio
Matei, Deliu Victor
Caraglia, Michele
Borghesi, Marco
De Berardinis, Ettore
Busetto, Gian Maria
Giovannone, Riccardo
Lucarelli, Giuseppe
Ditonno, Pasquale
Perdona, Sisto
Bove, Pierluigi
Castaldo, Luigi
Hurle, Rodolfo
Musi, Gennaro
Brescia, Antonio
Olivieri, Michele
Cimmino, Amelia
Altieri, Vincenzo
Damiano, Rocco
Cantiello, Francesco
Serretta, Vincenzo
De Placido, Sabino
Mirone, Vincenzo
Sonpavde, Guru
Terracciano, Daniela
[J]. MEDICINE, 2015, 94 (42) : e1861
[5] Bladder Cancer. Version 3.2020
Flaig, Thomas W.
Spiess, Philippe E.
Agarwal, Neeraj
Bangs, Rick
Boorjian, Stephen A.
Buyyounouski, Mark K.
Chang, Sam
Downs, Tracy M.
Efstathiou, Jason A.
Friedlander, Terence
Greenberg, Richard E.
Guru, Khurshid A.
Guzzo, Thomas
Herr, Harry W.
Hoffman-Censits, Jean
Hoimes, Christopher
Inman, Brant A.
Jimbo, Masahito
Kader, A. Karim
Lele, Subodh M.
Michalski, Jeff
Montgomery, Jeffrey S.
Nandagopal, Lakshminarayanan
Pagliaro, Lance C.
Pal, Sumanta K.
Patterson, Anthony
Plimack, Elizabeth R.
Pohar, Kamal S.
Preston, Mark A.
Sexton, Wade J.
Siefker-Radtke, Arlene O.
Tward, Jonathan
Wright, Jonathan L.
Gurski, Lisa A.
Johnson-Chilla, Alyse
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (03): : 329 - 354
[6] Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer
Greer, Joseph A.
Pirl, William F.
Jackson, Vicki A.
Muzikansky, Alona
Lennes, Inga T.
Heist, Rebecca S.
Gallagher, Emily R.
Temel, Jennifer S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 394 - 400
[7] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Kanda, Y.
[J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
[8] Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer
Kimura, Shoji
D'Andrea, David
Soria, Francesco
Foerster, Beat
Abufaraj, Mohammad
Vartolomei, Mihai D.
Iwata, Takehiro
Karakiewicz, Pierre I.
Rink, Michael
Gust, Kilian M.
Egawa, Shin
Shariat, Shahrokh F.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (03) : 179.e19 - 179.e28
[9] Preoperative C-Reactive Protein as a Prognostic and Therapeutic Marker for Colorectal Cancer
Koike, Yuhki
Miki, Chikao
Okugawa, Yoshinaga
Yokoe, Takeshi
Toiyama, Yuji
Tanaka, Koji
Inoue, Yasuhiro
Kusunoki, Masato
[J]. JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (07) : 540 - 544
[10] Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
Matsuki, Takashi
Okamoto, Isaku
Fushimi, Chihiro
Sawabe, Michi
Kawakita, Daisuke
Sato, Hiroki
Tsukahara, Kiyoaki
Kondo, Takahito
Okada, Takuro
Tada, Yuichiro
Miura, Kouki
Omura, Go
Yamashita, Taku
[J]. CANCER MEDICINE, 2020, 9 (14): : 5015 - 5024

← 1 2 3 →